LU LUPIN
Lupin Q2 2026
LULUPIN

Lupin Q2 FY26 results (Jul–Sep 2025) and concall

Healthcare · Concall AI · Call held 7 Nov 2025

Management summary

  • Lupin delivered a record Q2 FY26, with revenues exceeding INR 7,000 crores and EBITDA over INR 2,100 crores.
  • Strong performance across all key markets, particularly the US..
  • Significant margin expansion to 31.3% was achieved through a favorable product mix and operational efficiencies.
  • The company is strategically investing in complex products, biosimilars, and specialty platforms.
  • Also focusing on regulatory compliance and ESG initiatives, though it anticipates some margin tempering in H2 due to increased R&D and lower PLI income..

Source: Inve concall analysis and management guidance record.

Highlights

  • Total revenue from operations exceeded INR 7,000 crores and EBITDA surpassed INR 2,100 crores for the first time in company history.

  • EBITDA margin expanded by 750 basis points YoY and 470 basis points QoQ, reaching 31.3%.

  • Q2 FY26 marks the 13th consecutive quarter of YoY growth, demonstrating business model strength.

  • US business recorded sales of USD 315 million, a growth of 41% YoY and 11.5% QoQ, one of its highest to date.

What they filed

₹ Cr · quarterly
Line itemQ3 FY25Q4 FY25Q1 FY26Q2 FY26
Revenue4,208 4,486 5,709 4,068
EBITDA1,411 1,746 2,730 1,176
Net profit985 1,291 2,128 1,357
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Guidance & targets

Profitability

  • EBITDA Margin Profitability · FY26 · High confidence 25% to 26%

    Previously 24% to 25% → 25% to 26%

  • EBITDA Margin Profitability · FY27 · High confidence 24% to 25%

Source: Inve Guidance Tracker — management targets and direct quotes from the earnings call transcript.

Q&A highlights

2 direct
Tolvaptan revenue trajectory and key US launches for H2 FY26 and FY27 Direct
So, as we look at the next couple of quarters, the second half, we certainly think that we'll have some erosion from this USD 315 million, but we should be, close to between USD 275 million to USD 300 million per quarter to close over USD 1 billion as we have guided in the past.

Provides specific revenue expectations for a key US product (Tolvaptan) and outlines the pipeline of new launches expected to contribute to US revenue in the near future.

Asked by Kunal Dhamesha

EBITDA margin guidance for FY27 Direct
We expect a reduction in the second half. But we have also said in the same breath that there would be an increase in the R&D expenditure. But we do expect the R&D expenditure next year to kind of normalize a little vis-a-vis, in fact, the second half. And given the fact that we

Clarifies the company's long-term EBITDA margin outlook, indicating a slight tempering in H2 FY26 due to R&D but a stable range for FY27.

Asked by Kunal Dhamesha

Unlock risks & concerns, Q3 FY26 watchlist, and full call analysis

You’re reading a preview. Opening the full call uses 1 concall credit and unlocks:

  • 8 risks, concerns & management red flags
  • 5 watchlist triggers for Q3 FY26
  • +12 more guidance targets & verbatim management quotes
  • +6 more analyst Q&A exchanges & evasion checks
  • Capital allocation & full section-by-section narrative

Sign in to use your monthly call allowance.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared and our regulatory disclaimer. · Share on WhatsApp · Scorecard image